A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

NCT01662726 | Terminated Phase 2

• 3 other identifiers: C/24/20112011-005240-10X-52-58064-011
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

This study is investigating the effects of a new hormone treatment for breast cancer called Irosustat. Seventy percent of breast cancers in post-menopausal wome rely on oestrogen to grow therefore are likely to respond to hormone therapy. Irosustat blocks a different pathway of steroid synthesis to Aromatase, reducing in this way oestrogen levels in the body. As less oestrogen reaches the breast cancer, it grows more slowly or stops growing altogether. IPET will recruit postmenopausal women with early, hormone sensitive, treatment naive breast cancer will receive 40mg of Irosustat once daily for 2 weeks. The effects of Irosustat on breast cancer will be evaluated by PET scans (Positron Emission Tomography) using a radioactive substance called FLT as a tracer. The scans will be performed in a PET-CT scanner which combines a PET scan and a CT scan (Computer Tomography) into one scan. This type of scan can show how body tissues are working, as well as what they look like. FLT-PET scans will be performed before and following treatment with Irosustat. As cancer cells grow faster than the normal cells around them, they will take up more of the radioactive substance, and so stand out clearly on the scan. If Irosustat is slowing down the cancer growth, the cancer will take up less of the tracer. Blood samples will be taken at regular intervals to assess what the new drug does to the body and the safety and tolerability of Irosustat will be assessed. The study incorporates translation aspects/endpoints which are based on the collection of tumour biopsies before and after treatment with Irosustat although the later biopsy is not mandatory.

Conditions

Breast Neoplasms

Outcome Measures

Primary Outcomes (1)

• Changes in FLT uptake as assessed by PET following 2 weeks of treatment with Irosustat

  Patients will have a baseline FLT-PET/CT scan and a follow-up scan after 2 weks of treatment with Irosustat

Secondary Outcomes (2)

• To characterize the pharmacodynamic profile of Irosustat by measuring peripheral blood steroid hormone levels

  Blood samples will be drawn from patients on day 1, day 7, day 14 and 28 days post administration of the last dose of Irosustat

• To evaluate safety and tolerability of Irosustat by collecting toxicities according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03: June 14, 2010)

  Patients will be assesed at baseline, day 7, day 14 and at 30 days following the last dose of Irosustat. Patients who have consented to an optional post treatment tumour biopsy will attend an extra study visit.

Study Arms (1)

Irosustat

EXPERIMENTAL

Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.

Drug: Irosustat

Interventions

Irosustat DRUG

Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.

Also known as: BN83495, STX64, 667-coumate

Irosustat

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent to participate in the trial
• years of age or older
• Histologically confirmed ER +ve breast cancer (Allred ≥ 3)
• Any HER2 status
• Tumour measuring ≥ 15mm in longest diameter on ultrasound (US) examination
• Postmenopausal women as defined by any one of the following criteria:
• Amenorrhoea \> 12 months at the time of diagnosis and an intact uterus OR,
• prior bilateral oophorectomy OR,
• FSH levels within the postmenopausal range (as per local practice) in women aged \< 55years who have undergone hysterectomy OR,
• FSH levels within the postmenopausal range (as per local practice) in women aged \< 55 years who have been on Hormone Replacement Therapy (HRT) within the last 12 months and are therefore not amenorrhoeic
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
• Adequate bone marrow function defined by Hb ≥ 10 g/dl, WBC ≥ 3.0 x109, PLT ≥ 100 x109/L. Adequate renal function defined by a serum creatinine ≤ 1.5 x ULN. Adequate liver function defined by total bilirubin ≤ 1.5 ULN (patients with Gilbert's syndrome exempted), either ALT or AST ≤ 1.5 ULN and ALP ≤ 1.5 ULN

You may not qualify if:

• Locally advanced/inoperable breast cancer
• Clinical evidence of metastatic disease
• Diffuse or inflammatory tumours
• Any history of invasive malignancy within 5 years of starting study treatment (other than adequately treated basal cell carcinoma or squamous cell carcinoma of the skin and cervical carcinoma in situ)
• Evidence of bleeding diathesis and PTT and PT ≤ 1.5 x upper limit of normal
• Concomitant use (defined as use within 4 weeks prior to entry) of HRT or any other oestrogen-containing medication or supplement (including vaginal oestrogens and phytoestrogens)
• Previous use of oestrogen implants at ANY time.
• Concomitant use of:
• Rifampicin and other CYP2C and 3A inducers such as rifabutin, rifapentine, carbamazepine, phenobarbital, phenytoin and St. John's Wort
• Systemic carbonic anhydrase inhibitors
• Any of the following cardiac criteria:
• Mean resting corrected QT interval (QTcf) \> 450 ms obtained from 3 electrocardiograms (ECGs)
• Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block
• Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
• Uncontrolled abnormalities of serum potassium, sodium, calcium or magnesium levels

Sponsors & Collaborators

• Imperial College London: lead
• National Institute for Health Research, United Kingdom: collaborator
• Ipsen: collaborator
• Imperial College Healthcare NHS Trust: collaborator
• Guy's and St Thomas' NHS Foundation Trust: collaborator
• University of Southern California: collaborator
• QPS Netherlands B.V.: collaborator

Study Sites (1)

Imperial College Healthcare NHS Trust

London, London, W6 8RF, United Kingdom

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

irosustat

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Carlo Palmieri, BSc MBBS PhD

  Imperial Colllge London

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 7, 2012
• First Posted: August 10, 2012
• Study Start: August 1, 2012
• Primary Completion: July 1, 2014
• Study Completion: December 1, 2014
• Last Updated: March 14, 2016

Record last verified: 2013-08

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)